Puma Biotechnology, Inc. (PBYI) insider trading.
In Q3 2026, insiders at Puma Biotechnology, Inc. reported 6 non-derivative transactions on 5 Forms 3, 4 and 5: 0 open-market purchases and 5 sales worth $1.1M.
- Transactions
- 6
- Purchases (P)
- 0
- Sales (S)
- 5
- Net shares, P minus S
- -129,054
- Insiders
- 5
- Last filed
- 2026-09-16
Insiders
| Insider | Relationship | Transactions | Buys | Sales |
|---|---|---|---|---|
| Cesano Alessandra | Director | 2 | 0 | 1 |
| Wilson Troy Edward | Director | 1 | 0 | 1 |
| Nougues Maximo F | Officer · Chief Financial Officer | 1 | 0 | 1 |
| Hunt Douglas M | Officer · See Remarks | 1 | 0 | 1 |
| Auerbach Alan H | Director, Officer, TenPercentOwner · President and CEO | 1 | 0 | 1 |
Transactions
| Date | Insider | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-14 | Cesano Alessandra | S (D) | 62,150 | $9.12 | 56,700 | Form 4 |
| 2026-09-14 | Cesano Alessandra | M (A) | 50,000 | $2.93 | 118,850 | Form 4 |
| 2026-09-14 | Wilson Troy Edward | S (D) | 5,000 | $9.1 | 54,750 | Form 4 |
| 2026-07-06 | Nougues Maximo F | S (D) | 9,386 | $8.26 | 230,637 | Form 4 |
| 2026-07-06 | Hunt Douglas M | S (D) | 8,460 | $8.26 | 196,841 | Form 4 |
| 2026-07-06 | Auerbach Alan H | S (D) | 44,058 | $8.26 | 7,261,671 | Form 4 |
Transaction codes in this quarter
Get PBYI insider transactions through the API
curl "https://sec-api.dev/api/v1/insider-transactions?period=2026q3&cik=1401667&limit=100" \
-H "Authorization: Bearer $SEC_API_KEY"Insider trading API guide · PBYI company page · Puma Biotechnology, Inc. on SEC.gov
Questions
Are insiders buying or selling Puma Biotechnology, Inc. (PBYI)?
In Q3 2026, insiders at Puma Biotechnology, Inc. reported 6 non-derivative transactions on 5 Forms 3, 4 and 5: 0 open-market purchases and 5 sales worth $1.1M. Grants, tax withholding and option exercises are counted as transactions but are not purchases or sales.
Where do these Puma Biotechnology, Inc. insider trades come from?
From the SEC Insider Transactions Data Sets for Q3 2026, which republish the Forms 3, 4 and 5 filed on EDGAR. Each row links to its filing on SEC.gov.
Plain-text version for agents and LLMs: /insider-trading/pbyi.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.